Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer
Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer
复制标题
DOI：
10.1158/1078-0432.ccr-04-0861
复制
发表时间：
2005-04-15
影响因子：
11.5
通讯作者：
Hirashima, M
中科院分区：
文献类型：
--
作者：
Irie, A;Yamauchi, A;Hirashima, M
目的：半乳糖凝集素-9是β-半乳糖苷结合半乳糖凝集素家族的成员，诱导某些细胞类型的聚集。我们评估的贡献半乳糖凝集素-9的乳腺癌细胞的聚集，以及半乳糖凝集素-9在肿瘤组织中的表达和远处转移的乳腺癌patientswith breast cancer.Experimental Design：MCF-7乳腺癌细胞的亚克隆与高或低水平的半乳糖凝集素-9表达的建立，无论是培养在塑料皿或移植到裸鼠。采用免疫组织化学方法检测84例乳腺癌患者肿瘤组织中galectin-9的表达。患者随访了14 years.Results：MCF-7亚克隆与高水平的galectin-9的表达形成紧密的集群在体外增殖过程中，而亚克隆（K10）与galectin-9的表达水平最低没有。然而，用半乳糖凝集素-9表达载体稳定转染的K10细胞在培养物和裸鼠中聚集。半乳糖凝集素-9的异位表达也降低了MCF-7细胞与细胞外基质蛋白的粘附。84例患者中42例Galectin-9阳性，21例远处转移患者中19例Galectin-9阴性。Galectin-9阳性的13例淋巴结转移至11级的患者均无远处转移。galectin-9阳性患者的累积无病生存率高于galectin-9阴性患者（P < 0.0001）。多因素分析显示，半乳糖凝集素-9状态影响远处转移的独立和更大程度上比淋巴结transmittal.Conclusions：半乳糖凝集素-9是一个可能的预后因素与乳腺癌的抗转移潜力。
Purpose: Galectin-9, a member of the beta-galactoside - binding galectin family, induces aggregation of certain cell types. We assessed the contribution of galectin-9 to the aggregation of breast cancer cells as well as the relation between galectin-9 expression in tumor tissue and distant metastasis in patients with breast cancer.Experimental Design: Subclones of MCF-7 breast cancer cells with high or low levels of galectin-9 expression were established and either cultured on plastic dishes or transplanted into nude mice. The tumors of 84 patients with breast cancer were tested for galectin-9 expression by immunohistochemistry. The patients were followed up for 14 years.Results: MCF-7 subclones with a high level of galectin-9 expression formed tight clusters during proliferation in vitro, whereas a subclone (K10) with the lowest level of galectin-9 expression did not. However, K10 cells stably transfected with a galectin-9 expression vector aggregated in culture and in nude mice. Ectopic expression of galectin-9 also reduced MCF-7 cell adhesion to extracellular matrix proteins. Tumors of 42 of the 84 patients were galectin-9 positive, and those of 19 of the 21 patients with distant metastasis were galectin-9 negative. None of the13 patients with galectin-9- positive tumors and lymph node metastasis up to level 11 manifested distant metastasis. The cumulative disease-free survival ratio for galectin-9- positive patients was more favorable than that for the galectin-9- negative group (P < 0.0001). Multivariate analysis revealed that galectin-9 status influenced distant metastasis independently of and to a greater extent than lymph node metastasis.Conclusions: Galectin-9 is a possible prognostic factor with antimetastatic potential in breast cancer.